Project Details
Description
Social science has a long-standing interest in the pharmaceutical industry and its relations with the health system. A key area of concern is the large money sums paid or donated to other health system actors that could allow drug companies to convert their unrivalled financial resources into power over clinical and policy decisions. This internationally collaborative project employs a wealth of available payment data to map power relations involving the industry and medical associations and patient organisations – two actors with key roles in the health system. Informed by sociological and policy research, we examine the nature, structure, and determinants of payments; and their possible effects on the ‘industry-medical-patient complex’ within a global context. The project comprises a combination of light-touch country cases from Europe, Japan and the developing world and in-depth studies of three European countries - UK, Sweden and Latvia. The light-touch cases will involve Social Network Analysis of payment data. The in-depth cases will deploy also regression analyses of payments and other publicly available data, and thematic analysis of interviews with representatives of companies and payment recipients which will be sampled purposively based on their varying levels of inter-connectedness. The project will provide a novel theoretical and methodological toolbox for studying the nature and distribution of power which can inform research on other industries and sectors
| Status | Finished |
|---|---|
| Effective start/end date | 1/01/21 → 31/12/24 |
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.
-
Self-regulation of UK's pharmaceutical industry
Ozieranski, P., Mulinari, S., Colombo, C. & Mintzes, B., 28 May 2025, In: BMJ (Clinical research ed.). 389, p. r1065 r1065.Research output: Contribution to journal › Editorial › peer-review
1 Link opens in a new tab Citation (SciVal) -
Unknowns of drug company payment disclosure: why the UK needs payment transparency legislation
Ozieranski, P., Rickard, E. & Mulinari, S., 7 Jan 2025, (E-pub ahead of print) In: BMJ Evidence-Based Medicine. 6 p., bmjebm-2024-113101.Research output: Contribution to journal › Article › peer-review
Open Access3 Link opens in a new tab Citations (SciVal) -
Broken beyond repair: self regulation of industry payments to clinicians and hospitals
Ozieranski, P. & Mulinari, S., 12 Jul 2024, In: BMJ. 386, q1559.Research output: Contribution to journal › Comment/debate › peer-review
Open AccessFile6 Link opens in a new tab Citations (SciVal)227 Downloads (Pure)
Datasets
-
Dataset for "A patient-industry complex? Investigating the financial dependency of UK patient organisations on drug company funding"
Ozieranski, P. (Creator), Pitter, J. (Creator), Rickard, E. (Creator), Mulinari, S. (Creator) & Csanadi, M. (Creator), University of Bath, 7 Dec 2021
DOI: 10.15125/BATH-00904
Dataset